Annexon, Inc. Annexon, Inc.

Annexon, Inc.

ANNX

Rank in Stocks #9359
Annexon, Inc. is a biopharmaceutical company currently engaged in clinical... Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.
Share Price
$4.19
Last synced: 2026-11-11
Market Cap
$857.49M
Change (1 day)
-0.48%
Change (1 year)
38.74%
Country

Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this

Category

Healthcare
EPS for Annexon, Inc. (ANNX)
EPS as of September 2026 TTM: $-1.04
According to Annexon, Inc.'s latest financial reports, its current EPS (TTM) is $-1.04. At the end of 2025 the company had an EPS of $-1.34, a decrease compared to its 2024 EPS of $-1.01.
EPS history for Annexon, Inc. from 2017 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-1.04 -22.39%
2025 $-1.34 32.67%
2024 $-1.01 -42.94%
2023 $-1.77 -31.92%
2022 $-2.60 -22.16%
2021 $-3.34 -9.73%
2020 $-3.70 281.44%
2019 $-0.97 -39.38%
2018 $-1.60 226.53%
2017 $-0.49 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -14.42%
US
$15.66 -1,605.77%
US
$-7.07 579.81%
US
$-5.29 408.65%
AU
$12.73 -1,324.25%
BE

Questions about Annexon, Inc.'s earnings per share (EPS)

What is Annexon, Inc.'s earnings per share (EPS)?

Annexon, Inc.'s earnings per share (EPS) over the last twelve months is $-1.04, as of Sep 2026.

What was Annexon, Inc.'s earnings per share (EPS) in 2025?

In 2025, Annexon, Inc.'s earnings per share (EPS) was $-1.34, compared with $-1.01 in 2024.

How has Annexon, Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Annexon, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.01) and lowest in 2020 ($-3.70).

How does Annexon, Inc.'s earnings per share (EPS) compare with similar companies?

Annexon, Inc.'s earnings per share (EPS) ($-1.04) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.